Renal & Urology News4d
Fabhalta Approved as First Treatment for C3 Glomerulopathy
The FDA has approved Fabhalta (iptacopan) for the treatment of adults with complement 3 glomerulopathy (C3G), to reduce proteinuria.
Novartis Secures Third FDA Approval For Its Kidney Disease Portfolio In One Year
The U.S. Food and Drug Administration (FDA) on Wednesday granted accelerated approval for Novartis AG’s (NYSE:NVS) Vanrafia ...
FDA Grants Accelerated Approval to NVS Kidney Disease Drug
Novartis strengthens its renal disease portfolio with accelerated approval of another drug for immunoglobulin A nephropathy.
Novartis gets FDA accelerated approval for kidney disease treatment
Novartis (NYSE:NVS) said on Thursday that it received US FDA's accelerated approval for Vanrafia as a treatment for adults ...
The Financial Express5d
Novartis gets USFDA nod for its therapy to treat Berger’s disease
IgAN is a progressive, rare kidney disease in which the immune system attacks the kidneys, often causing glomerular ...